tailieunhanh - Báo cáo y học: "Pilot study of losartan for pulmonary hypertension in chronic obstructive pulmonary disease"

Tuyển tập các báo cáo nghiên cứu về y học được đăng trên tạp chí y học 'Respiratory Research cung cấp cho các bạn kiến thức về ngành y đề tài:"Pilot study of losartan for pulmonary hypertension in chronic obstructive pulmonary disease. | Respiratory Research BioMed Central Research Open Access Pilot study of losartan for pulmonary hypertension in chronic obstructive pulmonary disease Nicholas W Morrell 1 Matthew A Higham1 Peter G Phillips1 B Haleema Shakur1 Paul J Robinson2 and Ray J Beddoes2 Address Department of Respiratory Medicine Imperial College School of Medicine London UK and 2Medical Department Merck Sharp Dohme Limited Hoddesdon UK Email Nicholas W Morrell - nwm23@ Matthew A Higham - m@ Peter G Phillips - B Haleema Shakur - Paul J Robinson - paul_robinson@ Ray J Beddoes - Corresponding author Published 01 August 2005 Received II April 2005 Respiratory Research 2005 6 88 doi 1465-9921 -6-88 Accepted 01 August 2005 This article is available from http content 6 1 88 2005 Morrell et al licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License http licenses by which permits unrestricted use distribution and reproduction in any medium provided the original work is properly cited. Abstract Background Morbidity in COPD results from a combination of factors including hypoxia-induced pulmonary hypertension in part due to pulmonary vascular remodelling. Animal studies suggest a role of angiotensin II and acute studies in man concur. Whether chronic angiotensin-II blockade is beneficial is unknown. We studied the effects of an angiotensin-II antagonist losartan on haemodynamic variables exercise capacity and symptoms. Methods This was a double-blind randomized parallel group placebo- controlled study of 48 weeks duration. Forty patients with COPD and pulmonary hypertension Tran tricuspid pressure gradient TTPG 30 mmHg were randomised to losartan 50 mg or placebo. Changes in TTPG were assessed at 3 6 and 12 months. Results There was a trend for TTPG to increase in the .